University of Vermont Began Pancreatic Cancer Trial
The clinical trial evaluates a new drug-delivery technology for patients with borderline pancreatic cancer.
Updated on Oct. 8, 2026 in Biotech
Live Poll
Should cancer research prioritize developing targeted drug delivery systems over traditional systemic chemotherapy?
The University of Vermont has enrolled the first patient in the PRISM-TAMP clinical trial. The study tests the efficacy of delivering gemcitabine directly to tumor sites using the FDA-cleared RenovoCath device.
Why it matters
Researchers aim to determine if local chemotherapy delivery before surgery can improve tumor regression and patient surgical outcomes. This approach seeks to refine treatment protocols for those with borderline pancreatic ductal adenocarcinoma.
The PRISM-TAMP trial utilizes the FDA-cleared RenovoCath drug-delivery system to target gemcitabine directly near pancreatic tumors. The trial is currently registered under NCT07477418 to track surgical margins and tumor regression.
The players
University of Vermont
A public research university based in Burlington that serves as the sponsor and clinical site for the PRISM-TAMP study.
RenovoRx
A medical device company based in Mountain View, California, that developed the FDA-cleared RenovoCath platform.
The details
The PRISM-TAMP study monitors how localized delivery of chemotherapy drugs influences outcomes in patients with pancreatic ductal adenocarcinoma. The research focuses on assessing tumor size reduction and surgical viability after neoadjuvant treatment.
Timeline
2025: RenovoRx generated $1.1 million in RenovoCath sales.
Q2 2026: RenovoRx reported record quarterly revenue of $909,000.
August 2026: RenovoRx reached full enrollment in the TIGeR-PaC trial.
October 7, 2026: The first patient enrolled in the PRISM-TAMP clinical trial.
Second half of 2027: Expected topline data readout for the TIGeR-PaC trial.
The Tech Race
This development follows the trajectory of the TIGeR-PaC clinical trial, highlighting a shift toward localized drug delivery systems in oncology. It positions the RenovoCath platform as a key competitor against traditional systemic chemotherapy methods in the medical device market.
For patients and providers in Burlington, this trial introduces a new treatment methodology that could eventually change standards of care for pancreatic cancer. Success in the trial may lead to broader medical adoption of the RenovoCath delivery system in standard clinical practice.
The takeaway
Advancements in localized drug delivery offer a potential path toward better surgical outcomes for complex cancer cases. Patients should discuss new clinical trial opportunities with their oncology care teams to stay informed on emerging medical technologies.
Further reading
Learn more about the latest developments in the field in the Biotech section.
Live Poll
Should cancer research prioritize developing targeted drug delivery systems over traditional systemic chemotherapy?
